早期肺癌立体定向消融放疗与手术倾向评分研究的荟萃分析
该系统评价与荟萃分析纳入16项倾向评分研究,比较早期非小细胞肺癌患者接受立体定向消融放疗(SABR)与手术的生存结局。结果显示手术组总生存优于SABR(HR 1.48,95%CI 1.26-1.72),但肺癌特异性生存两组无显著差异(HR 1.17,95%CI 0.92-1.50)。
要点
- 手术组总生存优于SABR,但肺癌特异性生存无显著差异。
- 亚组分析中肺叶切除和亚肺叶切除的总生存均优于SABR。
- 手术组淋巴结升期率15.6%,11.4%患者接受化疗。
核心结论
- 对于适合两种治疗的早期非小细胞肺癌患者,手术较SABR显示更好的总生存。
- 两种治疗的肺癌特异性生存相似。
- 倾向评分分析的匹配卡尺距离和第一作者专业与生存终点相关。
研究设计与样本
- 纳入16项比较SABR与手术的倾向评分研究。
主要发现
- 总生存 favoring 手术:SABR vs 手术的风险比1.48(95%CI 1.26-1.72),I²=80.5%。
- 肺癌特异性生存无显著差异:风险比1.17(95%CI 0.92-1.50),I²=18.6%。
- 亚组分析中肺叶切除和亚肺叶切除的总生存均优于SABR,肺癌特异性生存仍无显著差异。
- 手术组淋巴结升期率15.6%,11.4%患者接受化疗。
关键数值与推荐
- 总生存风险比1.48(95%CI 1.26-1.72),I²=80.5%, favoring 手术。
- 肺癌特异性生存风险比1.17(95%CI 0.92-1.50),I²=18.6%,无显著差异。
- 手术组淋巴结升期率15.6%,化疗比例11.4%。
临床怎么用
- 对于可手术的早期非小细胞肺癌患者,手术可能带来更好的总生存,但需结合患者具体情况。
- SABR与手术的肺癌特异性生存相似,支持SABR作为替代选择。
- 倾向评分研究的匹配方法和作者专业可能影响生存结果解读。
局限性
- 无已完成的手术与SABR随机试验,仅基于倾向评分研究。
- 总生存分析存在高度异质性(I²=80.5%)。
- 倾向评分分析可能无法完全控制混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As no completed randomized trials of surgery versus stereotactic ablative radiation therapy (SABR) in patients with early-stage non-small cell lung cancer are available, numerous propensity score studies have attempted to mimic the setting of clinical trials using nonrandomized data. We performed a meta-analysis of propensity score studies comparing SABR and surgery. METHODS AND MATERIALS: The MEDLINE and Embase databases were queried up to December 2016. Two authors independently reviewed the records for inclusion and extracted outcome measures. The study was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines. The primary meta-analysis and secondary analyses were carried out using R (version 3.3.2) at a significance level of .05. RESULTS: Sixteen studies were included in the meta-analysis. Overall survival favored surgery (hazard ratio for SABR vs surgery, 1.48 [95% confidence interval, 1.26-1.72]; I2 = 80.5%). Lung cancer-specific survival was not significantly different between SABR and surgery (hazard ratio, 1.17 [95% confidence interval, 0.92-1.50]; I2 = 18.6%). On stratification, overall survival favored both lobectomy and sublobar resection over SABR, although lung cancer-specific survival was again not significantly different. On secondary analysis, the lymph node upstaging rate was 15.6% following surgery, with 11.4% of patients receiving chemotherapy. The propensity score-matching caliper distance and first-author specialty were found to be associated with survival endpoints on regression. CONCLUSIONS: For patients with early-stage non-small cell lung cancer who are eligible for either treatment, better overall survival was seen after surgery compared with SABR. However, lung cancer-specific survival was similar for both treatments. Prospective clinical trials are preferred to propensity analyses in evaluating the nature of non-cancer-related death after SABR.
引用
- Chen H, Laba JM, Boldt RG, et al. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. Int J Radiat Oncol Biol Phys. 2018. PMID: 29619964. doi:10.1016/j.ijrobp.2018.01.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。